RET and medullary thyroid gland carcinoma: An open-label, phase 1/2 ARROW study showed that the treatment with pralsetinib, a selective RET kinase inhibitor, resulted in complete response in 6.5% and partial response in 71.0% of the RET-mutant MTC patients [73].